Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seribantumab plus Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT01447706Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Oct 2011
- Primary completion
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of seribantumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Merrimack Pharmaceuticals. Started Oct 2011; status: completed.
02
Drugs
seribantumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01447706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01447706.